From Academic Excellence to Clinical Impact: The Launch of Adalid Sciences

We are proud to announce the formal launch of Adalid Sciences, a biotechnology spin-off from the Institute of Organic Chemistry and Biochemistry (IOCB Prague). Founded in June 2024, Adalid was born from a singular mission: to redefine the efficiency and safety of genomic medicine through next-generation delivery systems.

A Foundation of Scientific Rigor

The genesis of Adalid lies in years of multidisciplinary research at IOCB Prague, led by our co-founders Dr. Klara Grantz Saskova, Dr. Petr Cigler and Dr. Frantisek Sedlak, MD. Fourth co-founder, David Schreib will be heading the commercial operations of Adalid Sciences. By bridging synthetic chemistry with cellular biology, our team developed a proprietary platform of lipid nanoparticles (LNPs).

Advancing Genomic Medicine: Overcoming Delivery Bottlenecks

Unlike first-generation LNPs, the Adalid platform is engineered to address the critical bottlenecks of modern gene therapy. Our proprietary, modular lipid nanoparticle architecture offers:

• Efficacy: Maximized nucleic acid protection and optimized intracellular release, driving high-potency expression even at lower doses.
• Bypassing the Liver: Advanced, PEG-free outer shell architectures featuring click-ready stabilizers for flexible ligand attachment, enabling precise extrahepatic cell-type targeting.
• Low Immunogenicity: Highly biocompatible formulations engineered to minimize innate immune activation, unlocking the ability for safe, repeat dosing.

• Scalability: A modular architecture designed for seamless integration into existing GMP manufacturing workflows.

Strategic Backing for Long-Term Growth

The transition from bench to bedside requires more than just breakthrough science; it requires robust infrastructure. Adalid is backed by the BTL Group, providing the financial stability and commercial expertise necessary to navigate the complex landscape of global drug development. This partnership ensures that our focus remains on long-term value creation and reliable collaboration with our pharmaceutical partners.

Shaping the Future of Genomic Medicine

As we establish our headquarters in Prague, we invite the global biotech community—from seasoned researchers to strategic partners—to join us. Whether it is through fee-for-service optimization or deep-tech licensing, Adalid is ready to help our partners move their most promising candidates from discovery to clinical validation.

"In a fast-moving market like RNA and nucleic acid delivery, conversations matter as much as collaborations. We are building Adalid to be the partner of choice for those who refuse to settle for the status quo in drug delivery." — Klára Grantz Saskova, CEO

‍